Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Summit Central is NOW LIVE! Take a look at the virtual environment, discover content from the #ImmunologySummit2021 and much, much more!
— UCB News (@ucb_news) 13.10.2021 -
One in three women over 50 may experience a #fragilityfracture, a warning sign of #osteoporosis. To reduce your risk of future fractures, ACT now – speak to your healthcare professional or visit #ucb.com to find out more. #WOD2021.
— UCB News (@ucb_news) 13.10.2021 -
Visit https://t.co/33gbJ4Pg6o this #WorldArthritisDay to access helpful resources and information to help establish a gameplan to manage RA and other chronic inflammatory diseases - just like our #AdvantageHers partner @Carowozniacki!
— UCB News (@ucb_news) 12.10.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
